Literature DB >> 6027642

Resistance of long-lived lymphocytes and plasma cells in rat lymph nodes to treatment with prednisone, cyclophosphamide, 6-mercaptopurine, and actinomycin D.

J J Miller, L J Cole.   

Abstract

The cells of the popliteal lymph nodes of rats were labeled for 4 days after a secondary immunological stimulus. 31 days after the last dose of tritiated thymidine, groups of rats were started on courses of daily, intraperitoneal injections of prednisone, cyclophosphamide, 6-mercaptopurine, or actinomycin D. The initially low doses of these agents were doubled in successive weeks until either lymphoid hypoplasia or death occurred. Rats from each group were killed weekly, and the percentages of persisting, labeled small lymphocytes in the popliteal nodes were determined. Sections of these nodes were examined for persisting, labeled plasma cells. The per cent of lymphocytes labeled increased while the total number of lymphocytes decreased during treatment with prednisone and cyclophosphamide. Prednisone decreased the numbers of long-lived plasma cells, but these cells were preferentially resistant to cyclophosphamide. Neither 6-mercaptopurine nor actinomycin D had an appreciable effect on lymphoid tissues histologically nor on the proportions of labeled, long-lived lymphocytes and plasma cells before causing the deaths of the rats receiving them. These results indicate that long-lived lymphocytes and plasma cells survive treatment with the immunolytic drugs studied, and that long-lived lymphocytes are specifically resistant to prednisone and cyclophosphamide. We believe these results have an application to the attempts to find drugs useful in the treatment of immunologic rejections of organ transplants, and for therapy of autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 6027642      PMCID: PMC2138307          DOI: 10.1084/jem.126.1.109

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  20 in total

1.  AUTORADIOGRAPHIC STUDIES OF NUCLEIC ACID AND PROTEIN METABOLISM IN LYMPHOID CELLS. I. DIFFERENCES AMONGST MEMBERS OF THE PLASMA CELL SEQUENCE.

Authors:  J MITCHELL
Journal:  Aust J Exp Biol Med Sci       Date:  1964-06

2.  AN AUTORADIOGRAPHIC STUDY OF PLASMA CELL AND LYMPHOCYTE SURVIVAL IN RAT POPLITEAL LYMPH NODES.

Authors:  J J MILLER
Journal:  J Immunol       Date:  1964-05       Impact factor: 5.422

3.  STUDIES ON ADJUVANT-INDUCED POLYARTHRITIS IN RATS. 3. THE EFFECT OF "IMMUNOSUPPRESSIVE AGENTS" ON ARTHRITIS AND TUBERCULIN HYPERSENSITIVITY.

Authors:  J R WARD; R S CLOUD; E L KRAWITT; R S JONES
Journal:  Arthritis Rheum       Date:  1964-12

4.  DRUGS EMPLOYED FOR THE SUPPRESSION OF IMMUNOLOGIC RESPONSIVENESS.

Authors:  A C Aisenberg
Journal:  N Engl J Med       Date:  1965-05-27       Impact factor: 91.245

5.  POSSIBLE SPECIES DIFFERENCES IN RNA METABOLISM OF LYMPH NODE CELLS.

Authors:  J J MILLER; J MITCHELL
Journal:  Blood       Date:  1965-06       Impact factor: 22.113

6.  Basis of actinomycin action. I. DNA binding and inhibition of RNA-polymerase synthetic reactions by actinomycin.

Authors:  I H GOLDBERG; M RABINOWITZ; E REICH
Journal:  Proc Natl Acad Sci U S A       Date:  1962-12-15       Impact factor: 11.205

7.  The morphologic responses of the lymphoid system to homografts. II. The effects of antimetabolites.

Authors:  J A ANDRE; R S SCHWARTZ; W J MITUS; W DAMESHEK
Journal:  Blood       Date:  1962-03       Impact factor: 22.113

8.  [Modification of antibody formation by cytostatics and roentgen irradiation].

Authors:  H S STENDER; D RINGLEB; D STRAUCH; H WINTER
Journal:  Strahlentherapie       Date:  1959

9.  Specificity of immunosuppression by antimetabolites.

Authors:  R S Schwartz
Journal:  Fed Proc       Date:  1966 Jan-Feb

10.  The carriage of immunological memory by small lymphocytes in the rat.

Authors:  J L Gowans; J W Uhr
Journal:  J Exp Med       Date:  1966-11-01       Impact factor: 14.307

View more
  25 in total

Review 1.  Plasma cells as an innovative target in autoimmune disease with renal manifestations.

Authors:  Falk Hiepe; Andreas Radbruch
Journal:  Nat Rev Nephrol       Date:  2016-02-29       Impact factor: 28.314

2.  Antigenic competition between horse and sheep red blood cells as a hormone-dependent phenomenon.

Authors:  H O Besedovsky; A Del Rey; E Sorkin
Journal:  Clin Exp Immunol       Date:  1979-07       Impact factor: 4.330

Review 3.  The antinflammatory effects of glucocorticosteroids. A brief review of the literature.

Authors:  A M Dannenberg
Journal:  Inflammation       Date:  1979-07       Impact factor: 4.092

Review 4.  Antineoplastic and immunosuppressive drugs. I. Biochemical and clinical pharmacological considerations.

Authors:  A H Chalmers; L A Burgoyne; A W Murray
Journal:  Drugs       Date:  1972       Impact factor: 9.546

5.  Ultrastructural changes in murine peritoneal cells following cyclophosphamide administration.

Authors:  K N Chin; G Hudson
Journal:  Br J Exp Pathol       Date:  1974-12

6.  Failure of cytotoxic drugs to suppress immune responses of patients with rheumatoid arthritis.

Authors:  E J Denman; A M Denman; B M Greenwood; D Gall; R B Heath
Journal:  Ann Rheum Dis       Date:  1970-05       Impact factor: 19.103

7.  The effect of actinomycin-D on the haemopoietic and immune response to tetanus toxoid.

Authors:  B D Geller; R S Speirs
Journal:  Immunology       Date:  1968-11       Impact factor: 7.397

8.  Effects of cyclophosphamide on the ultrastructure of Peyer's patches.

Authors:  K N Chin; G Hudson
Journal:  Br J Exp Pathol       Date:  1970-12

9.  Plasma Cell Depletion Attenuates Hypertension in an Experimental Model of Autoimmune Disease.

Authors:  Erin B Taylor; Michelle T Barati; David W Powell; Hannah R Turbeville; Michael J Ryan
Journal:  Hypertension       Date:  2018-01-29       Impact factor: 10.190

10.  Effect of immunosuppressive agents on normal phage-neutralizing antibody in the mouse.

Authors:  R D Karp; S G Bradley
Journal:  J Bacteriol       Date:  1968-12       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.